Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 1

Status

Terminated 2Completed 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 6NIH 1INDIV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 2Lymphoid 2Other hematologic neoplasm 1NET 1Endocrine 1

Conditions

Breast Neoplasms 33Lymphoma 25Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Non-Hodgkin 12Leukemia 9Hodgkin Disease 9Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Multiple Myeloma 8Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Sarcoma 6Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Triple Negative Breast Neoplasms 5Neutropenia 5Lymphoma, B-Cell, Marginal Zone 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Prostatic Neoplasms 4Osteosarcoma 4Lung Neoplasms 4Waldenstrom Macroglobulinemia 3Testicular Neoplasms 3Sarcoma, Ewing 3Rhabdomyosarcoma 3Neuroblastoma 3Neoplasm Metastasis 3

Interventions

Surveys and Questionnaires 114Exercise 103Blood Specimen Collection 99Radiotherapy 67Gemcitabine 64Bevacizumab 57Standard of Care 56Cisplatin 55Cyclophosphamide 51Capecitabine 50Carboplatin 49Docetaxel 47pembrolizumab 46Dexamethasone 46Paclitaxel 45Interviews as Topic 43Oxaliplatin 40Magnetic Resonance Spectroscopy 39Fluorouracil 37Methods 36Irinotecan 36Therapeutics 33Drug Therapy 33Radiosurgery 31Nivolumab 30Erlotinib Hydrochloride 27Educational Status 26Everolimus 24Leucovorin 23Control Groups 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Neoplasms × pegfilgrastim × Clear all
NCT03943901 2026-01-29

Split-Dose R-CHOP for Older Adults With DLBCL

University of Wisconsin, Madison

Phase 2 Active not recruiting
27 enrolled 11 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00588094 2015-12-04

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
20 enrolled 6 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, B-Cell

NCT00410696 2013-07-01

Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy

Istituto Clinico Humanitas

Phase 2 Completed
80 enrolled
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT00751894 2011-01-19

MEG-5

University Hospital, Clermont-Ferrand

Phase 2 Unknown
30 enrolled
Tumor-Agnostic

Neoplasms

NCT00695370 2008-06-13

Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children

University Hospital, Clermont-Ferrand

Phase 2 Terminated
30 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡